The concomitant utilization of buprenorphine and CYP3A4 inducers can minimize the plasma focus of buprenorphine [see CLINICAL PHARMACOLOGY], potentially leading to decreased efficacy or onset of a withdrawal syndrome in individuals who have formulated physical dependence to buprenorphine.SUBUTEX ought to be put under the tongue until finally it rea